What Domperidon STADA Treats: Main Uses and Benefits

Domperidon STADA is relevant in contexts involving certain distressing gastrointestinal symptoms, applied across domains where additional symptomatic support is needed. Its therapeutic relevance applies to symptoms of slowed stomach emptying and the prevention of symptoms like nausea and vomiting associated with certain Parkinson's disease medications.

---

Therapeutic Focus and Symptom Management

The medication is commonly used to help with managing symptom clusters that may become intense or disruptive, including acute nausea, vomiting, and symptoms of slow gastric motility like post-meal fullness (early satiety) and persistent bloating. It is applied across domains where additional symptomatic support is needed, addressing issues in conditions such as gastroparesis, chronic dyspepsia, and even migraine-associated nausea.

This medicine is relevant in contexts where these symptoms interfere with daily functioning and may provide supportive relief that helps patients cope more steadily with difficult episodes.

“The medicine is applied in addressing symptoms that create noticeable functional strain, which contributes to easing the overall symptom load.”

Quick Fact: Addressing Post-Meal Fullness
Domperidon STADA may assist with addressing the uncomfortable feelings of early satiety and persistent bloating often linked to conditions where functional stability becomes affected in the upper digestive area.

Official Eligibility and Contraindication Profile

Domperidon STADA is strictly regulated, defining who is eligible for use based on age and existing health conditions, according to official regulatory labeling.

• Allowed Use: The medicine is licensed for Adults and Adolescents who are 12 years of age or older and weigh 35 kg or more. Use is permitted in patients with mild hepatic impairment.

• Absolute Contraindications: Use is strictly contraindicated in populations with known prolongation of cardiac conduction intervals (QTc), underlying cardiac diseases such as congestive heart failure, or significant electrolyte disturbances. It is also prohibited for patients with moderate or severe hepatic impairment, a prolactin-releasing tumour, or gastrointestinal conditions where motility stimulation would be harmful (e.g., hemorrhage, obstruction). Co-administration with certain QT-prolonging medicines or potent CYP3A4 inhibitors is also strictly prohibited.

• Restricted/Conditional Use: Patients with severe renal impairment maintain eligibility only if the dosing frequency is mandatorily reduced. Use is not recommended for children below the established age/weight threshold. Use is also not recommended during pregnancy or breastfeeding unless the anticipated benefit explicitly justifies the risk. Older patients (60 years and over) require caution due to a documented increase in cardiac risk.

This eligibility profile reflects the regulatory constraints focused on cardiovascular safety and metabolic function, which are the main determinants of eligibility for this medication.

Interactions with other medicines and products

Official regulatory information for Domperidon STADA establishes clear constraints regarding co-administration with other medicines and products.

Formal Contraindications

The use of Domperidon STADA is strictly contraindicated with two primary categories of substances due to the risk of serious interaction. This includes all potent inhibitors of the CYP3A4 enzyme, such as systemic azole antifungals and macrolide antibiotics, as these agents cause a significant, documented increase in Domperidone's systemic exposure. Similarly, Domperidon STADA is formally prohibited with any medicine known to prolong the QTc interval because of the risk of an additive pharmacodynamic effect on cardiac conduction. Grapefruit juice is also classified as a prohibited substance due to its enzyme inhibitory properties.

Pharmacokinetic and Timing Rules

Interactions may also arise with gastrointestinal agents. Antacids and antisecretory agents are documented to reduce the oral bioavailability of Domperidone and therefore must not be taken simultaneously.

Population-Specific Constraints

Domperidon STADA is contraindicated in specific patient populations because underlying conditions amplify the severity of documented interactions. These restrictions include patients with moderate or severe hepatic impairment or significant electrolyte disturbances (such as hypokalaemia), as these states heighten the risk profile associated with pharmacokinetic and pharmacodynamic interactions.

How Domperidon STADA Works

Domperidone functions as a peripherally-selective dopamine D2 and D3 receptor antagonist. This mechanism primarily engages specific receptor targets within the gastrointestinal tract and the area postrema (chemoreceptor trigger zone, CTZ).

---

Dopamine Receptor Antagonism

Domperidone's interaction involves the competitive blockade of D2/D3 receptors. In the peripheral system, this antagonism counters the natural inhibitory effects of dopamine on smooth muscle activity. This action modifies early molecular steps, thereby promoting neurotransmitter release (acetylcholine) that facilitates motor function.

---

System-Level Modulation

In the upper gastrointestinal tract, this blockade leads to increased force and duration of smooth muscle contractions and elevated tone of the lower esophageal sphincter, modulating gastrointestinal transit. In the CTZ, which lies outside the blood-brain barrier, D2 receptor antagonism disrupts afferent signaling sequences, leading to the suppression of the vomiting center activation in the medulla.

The administration of Domperidon STADA follows specific instructions regarding dose, timing, route, and duration, which are designed to ensure consistent delivery of the active substance.

Administration Scope

Property	Detail
Route of administration	Oral (for tablets and suspension) and Rectal (for suppositories).
Dosing schedule	Adults/Adolescents (ge 12 years, ge 35 kg): 10 mg per dose (tablet or 10 ml suspension). Pediatric (lt 35 kg): 0.25 mg/kg oral suspension per dose.
Timing in relation to meals	Oral forms must be taken before meals to avoid the delayed absorption that occurs when taken after food.
Preparation requirements	Oral suspension must be measured using a graduated oral syringe or a suitable device for accurate dosing; tablets should be swallowed whole with water.

Frequency and Duration Protocol

The medicine is typically administered up to three times per day orally, with a required interval of approximately 8 hours between doses. The total daily oral dose for adults and adolescents should strictly not exceed 30 mg. Treatment for acute symptoms should generally not exceed one week (seven consecutive days), and the drug must be used at the lowest effective dose for the shortest duration necessary.

Population-Specific Use

Patients with severe renal impairment require a mandatory reduction in dosing frequency to once or twice daily, depending on the severity of the impairment. For children weighing less than 35 kg, only the oral suspension is appropriate due to the need for accurate, weight-based dosing. If a scheduled dose is missed, it should be omitted, and the next dose should be taken at the usual time; the dose must not be doubled.

Recent Clinical Evidence

Overview of Efficacy Research

Clinical research has largely explored the use of domperidone in relieving symptoms associated with gastric motility disorders, such as nausea and vomiting. As a prokinetic agent, the drug's use is studied for its potential to help coordinate the movement of the gastrointestinal (GI) tract.

Studies have been conducted across various GI conditions:

• Gastroparesis: Trials have investigated the drug's use in refractory gastroparesis (delayed stomach emptying) in patients who have not responded to standard therapy. These studies often measure changes in patient-reported symptoms like bloating and pain.
• Nausea/Vomiting: The drug is specifically studied for the relief of nausea and vomiting symptoms. However, some large-scale randomized trials in pediatric populations (specifically children under 12 years with acute gastroenteritis) did not report a difference in symptom relief compared to placebo.

Safety and Regulatory Focus

Due to the reported association between domperidone use and the risk of cardiac side effects, safety monitoring and clinical evidence have centered on minimizing this risk. Regulatory bodies across Europe have updated guidance based on comprehensive reviews:

Risk Factor	Higher Risk Associated With
Dose	Daily doses exceeding 30 mg
Age	Patients over 60 years
Co-medication	Taking potent CYP3A4 inhibitors or other QT-prolonging medicines

These reviews have led to the current restriction of domperidone to the lowest effective dose for the shortest possible duration, usually not exceeding one week for acute symptoms of nausea and vomiting. The drug is contraindicated in individuals with certain pre-existing heart conditions or severe hepatic impairment.

Key Studies & References

1. Domperidone: Summary of Product Characteristics (SPC) - Contraindications and Warnings

Common questions about Domperidon STADA (FAQ)

Q: What is Domperidon STADA used for?

A: Domperidon STADA contains the active substance domperidone. It is used to provide symptomatic relief for nausea and vomiting in adults and adolescents aged 12 years and older and weighing 35 kg or more.

Q: How does domperidone work in the body?

A: Domperidone is classified as a dopamine antagonist. It is generally understood to act on the upper digestive tract to help promote the movement of food. The action is thought to help relieve symptoms of feeling sick and being sick.

Q: How long does the effect of Domperidon STADA typically last?

A: The period during which the effects of domperidone may be observed can vary among individuals. In clinical studies, relief of gastric symptoms was sometimes reported within 3 to 4 days of use. Healthcare providers generally advise using this medicine for the shortest possible time.

Q: Is Domperidon STADA associated with any risks to the heart?

A: Regulatory reviews have established that domperidone may be associated with a small increased risk of serious heart-related side effects, specifically involving the heart rhythm. The risk may be higher in individuals over 60 years of age or when higher daily doses are used. Due to this potential risk, it is important for the drug to be taken at the lowest effective amount and for a limited duration.

Q: Can Domperidon STADA be taken with other medicines?

A: Taking domperidone with certain other medicines may increase the risk of heart-related side effects. Examples of medicines that may interact include certain types of antifungals, antibiotics, and medicines for heart conditions. It is essential to discuss all current medications, including over-the-counter products and herbal supplements, with a healthcare provider before starting treatment.

Q: Who should not take Domperidon STADA?

A: Domperidon STADA is not suitable for everyone. It should generally be avoided by individuals who have:

• A known allergy to domperidone or any of its ingredients.
• A moderate or severe liver condition.
• Certain heart conditions, such as heart failure or specific changes on an ECG (electrocardiogram).
• Significant stomach or bowel issues, such as gastrointestinal bleeding or an obstruction.
• A tumour of the pituitary gland called prolactinoma.

Consultation with a prescribing physician is required to determine suitability.

Storage Requirements

Domperidon tablets must be stored according to strict regulatory conditions to ensure product quality and stability. The medicine must not be stored above 30 °C (30 degrees Celsius). It is explicitly required that the product be stored in the original package in order to protect from light and moisture. Furthermore, official labeling states that the tablets must not be refrigerated or frozen. Like all medicines, Domperidon STADA must be kept out of the sight and reach of children.

Disposal Instructions

There are no special requirements listed in the European regulatory documents for the disposal of the used medicinal product. However, disposal guidelines advise against throwing any medicines away via wastewater or household waste. Unused or expired medication should be safely returned to a pharmacist or an approved take-back program for proper disposal, which complies with environmental protocols and local waste regulations.